Business Description
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Business History
Generated: Jun 13, 2026 3:03amPrice Overview
Last updated: Jun 13, 2026 3:00am (14d ago)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 0.23
Total Equity: -$70.79M
Shares: 324,805,000
Total Debt: $2.63B
Cash: $310.87M
EBITDA: $603.87M
Total Debt: $2.63B
Cash: $310.87M
Revenue: $3.02B
Revenue: $3.02B
Revenue: $3.02B
Total Equity: -$70.79M
Tax Rate: 8.1%
Equity: -$70.79M
Total Debt: $2.63B
Cash: $310.87M
Current Liabilities: $881.63M
Long-Term Debt: $2.61B
Total Debt: $2.63B
Total Equity: -$70.79M
Shares: 324,805,000
Shares: 324,805,000
CapEx: -$70.06M
Shares: 324,805,000
Stock Price: $16.20
Net Income: $72.06M
Industry Benchmarks
Advanced Analysis Forensic deep-dive · three lenses
Amneal is genuinely executing on the business: revenue compounded from $2.09B (2021) to $3.02B (2025), gross margin expanded modestly from 36.7% to 37.6%, and operating margin stepped up sharply to 14.0% from 7.3% in 2021 (with a -4.3% trough in 2022). FCF has normalized in the $220-276M range the last three years, and OCF/NI of 4.07x with accruals at -8.5% of assets and a Beneish M of -2.71 suggest the reported numbers are backed by cash — earnings quality screens clean.
The quality concerns are structural, not cosmetic. Net debt of $2.32B against just $310.9M cash and ~$270M FCF implies a multi-year deleveraging runway, and Altman Z of 2.18 sits in the grey zone — the balance sheet is a constraint. Diluted shares jumped from 176.1M (2023) to 309.0M (2024) to 324.8M (2025), an 85%+ increase in two years, which looks like the Class B/LLC unit conversion (Amneal collapsed its Up-C structure) rather than ongoing equity issuance — SBC is only 1.1% of revenue, consistent with that read. Either way, per-share economics were materially reset, and net income has only just turned positive ($72.1M in 2025) after three loss years.
Insider tape is non-directional: a single $451K sale by Autor against routine award/exercise activity tells you nothing. The business is real, improving, and self-funding — but levered and with a recently restructured cap table, this is a Mixed-quality enterprise, not a fortress.
Verify before trusting this (6)
- Confirm the 2023→2024 share count jump (176M→309M) was the Up-C/LLC unit conversion (no new economic dilution) vs. genuine issuance
- Debt maturity schedule and refinancing exposure given $2.32B net debt
- Customer concentration with the major drug wholesalers (Cencora/Cardinal/McKesson) typical of generics
- Pipeline/ANDA approvals supporting durability of the revenue growth and the recent margin step-up
- Whether the 14.0% operating margin in 2025 reflects sustainable mix shift (biosimilars, specialty, AvKARE distribution) or one-off favorable comps
- Working capital sustainability of the 4.07x OCF/NI ratio — is it driven by one-time inventory/payables swings?
Amneal trades at a $5.17B equity cap and roughly $7.5B EV after $2.32B net debt. For a generics/specialty/AvKARE platform generating real free cash flow with improving operating margins, an EV/EBITDA in the 8–9x zone on stabilizing EBITDA is reasonable — implying deserved equity somewhere in the high-teens once you net the debt. That puts fair value modestly above $16, not multiples higher. The e2e synthesis flags 'High Conviction Required,' which I read as the methods disagreeing — DCFs on a levered, low-growth generics name swing wildly, so I weight EV/EBITDA and FCF yield more heavily.
The earnings-quality screen is clean (score 2), so no haircut there, but the Company-Quality lens is Mixed (-10) because of leverage and the doubled share count. That tempers deserved per-share value: equity holders are second in line to ~$2.3B of debt, and any multiple expansion accrues partly to the lenders. Bull case (scale advantage in a consolidating generics market, AvKARE optionality) supports mid-$18–20; bear case (price erosion, refinancing risk) supports $12–14. Midpoint sits roughly where the stock trades.
Net: a single-digit-percent discount to deserved value is real but not a fat pitch. This is 'modestly cheap, not a table-pound.'
Verify before trusting this (5)
- Latest net debt and refinancing schedule — any 2025/26 maturities at higher rates would lower deserved equity value
- Generics segment price/volume bridge in recent 10-Q to confirm margin trend is durable, not mix-driven
- AvKARE growth trajectory and contract concentration — the bull case leans heavily on this segment
- FCF guidance and capex run-rate — confirms the EBITDA-to-FCF conversion the valuation depends on
- Specialty pipeline milestones (any branded asset that would re-rate the multiple)
AMRX sits in a quiet sentiment pocket. The market regime is neutral with a slight risk-off lean (VIX 17.3, S&P off the highs), and while AMRX's 1.32 beta would normally amplify any tape stress, the tape itself isn't actively selling. The narrative is the bigger tell: a steady-compounder story with minimal intensity, moderate durability, and zero cult following. That means no euphoric bid to fade and no breaking story to short - the stock is simply not a vehicle anyone is using to express a macro view right now. Generics as a cohort lack a hot narrative thread (no AI angle, no GLP-1 halo, no obesity tie-in), so AMRX is invisible rather than embattled. Analyst tone is mildly constructive (10 Buys, 6 Holds, no Sells) but the consensus target of $17.33 sits only 3.8% above spot, with zero revisions this month - that is a textbook 'tapped out' setup where the sell side has already written the story and isn't adding fuel. The divergence to watch is small: analysts are nominally positive while the live narrative is dormant, suggesting upside surprises in flow are unlikely without a fresh catalyst. Net: macro headwinds from 4.48% 10y and stretched market PE press lightly on a 1.32-beta name, but the absence of a story to break offsets it. Pressure is balanced, leaning faintly negative.
Verify before trusting this (5)
- Any FDA approval, launch, or M&A headline that could ignite a real narrative (currently dormant)
- Generic pricing data points - a fresh deflation cycle would crack the steady-compounder story
- Sell-side target revisions - first upgrade or downgrade after a quiet month signals the next direction
- Whether VIX breaks 20 and regime flips risk-off, which would meaningfully hit a 1.32-beta name
- Sector rotation flows into defensive healthcare vs out of low-multiple generics
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 13, 2026 3:07am (14d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B |
| Cost of Revenue | $1.3B | $1.4B | $1.5B | $1.8B | $1.9B |
| Gross Profit | $769.0M | $791.5M | $863.9M | $1.0B | $1.1B |
| Operating Expenses | $616.3M | $886.4M | $659.5M | $771.1M | $713.0M |
| Operating Income | $152.7M | -$94.9M | $204.4M | $249.3M | $423.1M |
| Net Income | $10.6M | -$130.0M | -$84.0M | -$116.9M | $72.1M |
| EBITDA | $401.1M | $440.2M | $500.8M | $439.8M | $603.9M |
| EPS | $0.07 | $-0.86 | $-0.48 | $-0.38 | $0.23 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 13, 2026 3:00am (14d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $247.8M | $26.0M | $91.5M | $110.6M | $310.9M |
| Total Current Assets | $1.5B | $1.4B | $1.4B | $1.6B | $1.9B |
| Total Assets | $3.9B | $3.8B | $3.5B | $3.5B | $3.7B |
| Current Liabilities | $677.2M | $752.8M | $846.6M | $1.1B | $881.6M |
| Long-Term Debt | $2.7B | $2.6B | $2.4B | $2.2B | $2.6B |
| Total Liabilities | $3.6B | $3.6B | $3.4B | $3.5B | $3.7B |
| Total Equity | $360.3M | $298.4M | $19.8M | -$109.3M | -$70.8M |
| Retained Earnings | -$276.2M | -$406.2M | -$490.2M | -$607.1M | -$535.0M |
Cash Flow (Annual)
Last updated: Jun 13, 2026 3:07am (14d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $241.8M | $65.1M | $345.6M | $295.1M | $340.0M |
| Capital Expenditure | -$47.7M | -$90.6M | -$69.2M | -$75.0M | -$70.1M |
| Free Cash Flow | $194.1M | -$25.5M | $276.4M | $220.1M | $269.9M |
| Acquisitions (net) | -$141.5M | -$84.7M | $0 | $12.0M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$90.4M | -$221.5M | $63.9M | $19.3M | $194.5M |
Analyst Estimates (Annual)
Last updated: Jun 13, 2026 3:00am (14d ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$3.0B $3.0B – $3.0B
|
$3.1B $3.1B – $3.1B
|
$3.3B $3.3B – $3.4B
|
$3.6B $3.6B – $3.6B
|
| EBITDA |
$576.6M $574.7M – $578.5M
|
$593.9M $589.3M – $595.8M
|
$640.6M $636.7M – $642.5M
|
$683.2M $681.2M – $685.1M
|
| Net Income |
$261.5M $256.5M – $266.4M
|
$319.1M $314.3M – $323.9M
|
$367.7M $350.3M – $385.0M
|
$425.7M $421.9M – $429.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 13, 2026 3:07am (14d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +5.7% | +8.2% | +16.7% | +8.0% |
| Gross Profit Growth | +2.9% | +9.1% | +18.1% | +11.3% |
| Operating Income Growth | -162.2% | +315.3% | +22.0% | +69.7% |
| Net Income Growth | -1,323.5% | +35.4% | -39.2% | +161.6% |
| EBITDA Growth | +9.8% | +13.8% | -12.2% | +37.3% |
Insider Trading (Recent)
Last updated: Jun 13, 2026 3:06am (14d ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-11 | Autor Deborah M. | S-Sale | 34,819.00 | $12.94 | $450,558 |
| 2026-05-07 | BUCHI J KEVIN | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-06 | BUCHI J KEVIN | A-Award | 19,824.00 | $0.00 | $0 |
| 2026-05-07 | BUCHI J KEVIN | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-07 | Autor Deborah M. | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-06 | Autor Deborah M. | A-Award | 19,824.00 | $0.00 | $0 |
| 2026-05-07 | Autor Deborah M. | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-07 | George Jeffrey P. | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-06 | George Jeffrey P. | A-Award | 19,824.00 | $0.00 | $0 |
| 2026-05-07 | George Jeffrey P. | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-07 | Patel Gautam | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-06 | Patel Gautam | A-Award | 19,824.00 | $0.00 | $0 |
| 2026-05-07 | Patel Gautam | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-07 | Kiely John | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-06 | Kiely John | A-Award | 19,824.00 | $0.00 | $0 |
| 2026-05-07 | Kiely John | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-07 | Nark Ted C | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-06 | Nark Ted C | A-Award | 19,824.00 | $0.00 | $0 |
| 2026-05-07 | Nark Ted C | M-Exempt | 34,819.00 | $0.00 | $0 |
| 2026-05-07 | MEISTER PAUL M | M-Exempt | 48,747.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).
Delvantic AI Findings
Looking at the raw trajectory first: revenue ramped from $701.8M (Q2'24) to $814.3M (Q4'25), then dropped to $722.5M in Q1'26 — that's a 11% sequential decline, though Q1 seasonality is real in generics. More importantly, net income tells a cleaner story: -$31M → +$12M → +$22M → +$2M → +$35M → +$62M. The Q1'26 $62.5M print at 8.6% margin is the highest absolute earnings in the dataset by a wide margin, and it came on a sequentially weaker revenue base — meaning either mix shift toward Specialty/branded, one-time items, or genuine operating leverage. Full-year 2025 delivered $3.02B revenue (+8.2%), $423M operating income (+70% YoY), $340M OCF, $270M FCF. On $5.17B market cap, that's ~5.2% FCF yield and ~12x EV/EBITDA — not cheap, not egregious for a company that just doubled operating income.
The synthesis verdict of "High Conviction Required" feels like a hedge. The pre-flight thesis that the market still prices this as "permanently subscale" is half-wrong — at 43x TTM P/E and 12x EV/EBITDA, the market has clearly already paid for the turnaround; the stock 2x'd from $7.67. The narrative engine calling this a "steady-compounder" with "minimal" intensity is closer to right, but understates that AMRX is structurally levered (negative book equity is the giveaway — debt is conspicuously missing from the balance sheet section, which is a real gap given this is a leveraged generics roll-up; net debt is likely $2.5-3B based on the EV-to-market-cap implied gap, putting EV near $7.5-8B). At 2.1x EV/Sales for a generics-heavy business with mid-teens operating margins, you're paying specialty pharma multiples for a business still ~70% commodity generics by revenue.
The contrarian case the models underweight: Q1'26's $62.5M NI may not be sustainable. Generic pricing erosion is structural (3-7%/yr), the Specialty pipeline (Crexont/IPX-203 for Parkinson's, biosimilars) needs to do heavy lifting just to offset that, and AvKARE's government-channel margins are thin. The FCF CAGR of -1.2% versus revenue CAGR of +12.3% is the tell — they're growing the top line but cash conversion is deteriorating, likely from working capital build for biosimilar launches and Specialty inventory. Insider activity is uniformly sells against option exercises — nothing alarming for a pharma, but zero open-market buying near $16 from people who watched it at $7. The negative book equity means any covenant tightening or rate refi cycle bites hard; this is exactly the kind of name that re-rates down 30% in a credit scare without earnings missing.
I dissent mildly from the synthesis. This isn't "High Conviction Required" — it's a moderately overvalued levered turnaround where the easy money has been made. Fair value math: $270M FCF growing 5-7% (realistic blend of Specialty growth offsetting generic erosion), 9% discount rate, accounts for leverage risk → equity FV around $4.0-4.5B, or $12.5-14/share. To justify $16+ you need the Specialty/biosimilar mix to push consolidated operating margin from 14% toward 18-20% sustainably, which requires Crexont to actually ramp and biosimilars (denosumab, etc.) to land share. Possible, not probable at this multiple. The Q1'26 margin print is the bull's best ammunition but also the bear's setup for disappointment when Q2 normalizes. I'd want to see two more quarters of >7% net margins before paying 12x EV/EBITDA on a balance-sheet-impaired generics name.
GPT Critique
Amneal Pharmaceuticals presents a complex picture, with its recent financial performance showing both promise and caution. The company's revenue trajectory has been generally positive, with a 12.3% compound annual growth rate over the recent periods. However, the revenue fluctuation from $814.3 million in Q4'25 to $722.5 million in Q1'26, a notable 11% sequential decline, raises questions about the sustainability of its growth and whether this is a seasonal dip or indicative of deeper issues. The Q1'26 net income of $62.5 million, boasting an 8.6% margin, suggests significant improvement, but this came on a lower revenue base, which might suggest a favorable mix shift or perhaps a one-off gain rather than a sustainable trend. The financial health of the company is further complicated by its negative book equity, signaling potential leverage issues not fully detailed in the balance sheet data provided.
Opus argues that the market has already priced in Amneal's turnaround, citing the stock's doubling price from $7.67 to $16.20 and a current valuation of 43x P/E and 12x EV/EBITDA. I concur with this assessment, as these multiples suggest a market expectation of sustained profitability and successful transition into specialty pharma. However, I find the assertion that the market is still treating Amneal as "permanently subscale" to be somewhat misplaced given these valuations. The leverage concerns highlighted by Opus, particularly the potential $2.5-3B net debt, align with my view that the financial structure could pose significant risks if market conditions tighten or if operational execution falters.
I diverge from Opus on the conclusion regarding the company's valuation. While Opus finds the stock "mildly overvalued," I see the risks associated with its negative book equity and the need for a proven specialty mix shift as more significant, suggesting a potential overvaluation beyond mild. The current price of $16.20 appears to require an optimistic scenario where specialty and biosimilar divisions significantly improve margins, a scenario that may not be probable without clear evidence of pipeline success, particularly with products like Crexont and biosimilars. The insider selling trend without corresponding open-market purchases further reflects a lack of internal confidence at current valuations.
For a skeptic, both mine and Opus's analyses might underplay the potential for Amneal's specialty initiatives to fail to offset generic pricing pressures, which historically erode 3-7% annually. A careful skeptic would argue that the company's recent profitability might be transient, bolstered by one-time factors rather than sustainable shifts. The reliance on a successful specialty and biosimilar rollout, amidst heavy competition, could be overly optimistic, especially with the company's financial leverage posing an existential risk in a rising interest rate environment.